Member Info for Porky9

@Ad4you
Nice one, as you say "Significant" on top of already significant sales.
fantastic

@peka
Exactly the point. Oxford Nanopore is not the only example there are numerous others.

The main reason is because initially they actually didn't know how to rate Novacyt, was it going to be a one trick pony, was Covid going to blow over quick, did the business have any Longevity, so it was on effectively stuck on a cash rating.

That changed recently, the Framework deal was over 4 years, the market can see that Covid is not going away, we will need to adjust to it. The company revenues are strong and Diagnostics needs to be further embedded in the UK. The framework confirmed the business now has real LONGEVITY.

There is EVERY chance. probably that once the full audit accounts are published that we could see a proper rerate and a decent PE ratio allocated. Time will tell and i really hope so.

At the moment the SP is cheap as chips frankly. Hope this helps?

@Joker
Seriously you have no idea.
I completed my initial research, I have been stake building here for months and hold shares at numerous price points between 3.62 and 10.12 and I'm continuing to add. I have my price target, That's the way it is.
Everyone can trade their own way, it matters not to me
Good luck if you want 10%, 100%, 1000% or whatever return you want, that's your call / own goal
Good Luck

I keep saying, KEY POINT, only 70 m of shares in issue. That is very small compared to other stocks
12% in II hands and the balance half France/half UK
SP can move materially higher as a result with enough interest.

Currently Interest is building - Superb...

Even at 520 our Mcap is a mere £ 357m

The company has effectively now got all bases covered. In addition, they recently declared first quarter confirmed revenue of £ 72.6 m invoiced and in the bag.
Additional Revenues from new products will be, to quote, "Substantial"

We estimate the cash at bank to the end of March to be in the region of about £ 130 m.
To end of 2020 Financial Year they declared (in euros):-
Revenue 311.6m with EBITDA 210.8m

I mean, is this just a gift of a share price at this level... without doubt multibagger from here....

You can see why the market is going crazy to buy in...

GLA

LMOL
Come on Rocket Novacyt....
A close north of 550 today would be a very good start....
The sooner we are back above £ 10 the better, above £ 20 and all the crap here will be well worth the pain....
Good luck all Genuine holders...
Onwards and upwards

oh i mean...
Can you just imagine it if it turns out that they can invoice the extra £ 27m for the minimum order value...
Get in there....

Quarter 1 - £ 72.6 million already invoiced and in the bag.
+ Revenues from new products will be, ahem to quote "Substantial"
Just Love it, bring it on.....

In the words of Theo Paphitis " Lets see them tills a ring-a -ding -ding -in"
Happy Days, Have a great afternoon
Pork's

Looks like 650,000 in shorts still to buy back??
Will add to the buying volume..
This is lining up now something superb.... lets see this multibag from here to new ATHs
GLA

Let's face it the R&D and UK Operational Update on Friday was superb. Possibly the best update in the companies history to date as far as I'm concerned. PDF of full details here:-
https://novacyt.com/wp-content/uploads/2021/04/Novacyt-RD-Update-ENGLISH-Final-23.04.21.pdf

Those that haven't the time to read the full update this single image speaks a thousand words :
https://twitter.com/Porky9Here/status/1386454505311674368/photo/1

Key takes for Speed:-
* LFT Antibody Test - differentiate between IgG antibodies (Vaccine or Natural)
* LFT Antigen Test - able to detect the virus regardless of known mutations
* Saliva Test - critical for use in airport test and release programmes
* PHE Framework & NHS Continue supply - 50 new staff

Bottom line: The company has effectively now got all bases covered. In addition, they recently declared first quarter confirmed revenue of £ 72.6 m

We estimate the cash at bank to the end of March to be in the region of about £ 130 m.
To end of 2020 Financial Year they declared (in euros):-
Revenue 311.6m with EBITDA 210.8m
https://novacyt.com/wp-content/uploads/2021/02/SP-Angel-Update-04.02.2021.pdf

They supply 150 countries worldwide with 550 different products

It's easy to see why the market is starting to get excited again about this business

Good Luck

Of course one thing that Novacyt are good at is R&D, if anyone can perfect a scientific process or components of to deliver the highest levels of sensitivity and specificity in a test they can.

It might not be Aptamer Group and i could well be barking up the wrong tree but this feels to me more like a specialist lab delivering next-generation aptamers that could then come into the group rather than partnering with a company on a revenue share or some other deal.

At some point they have to do something with this cash mountain. I thought last month they would try and pick Cignpost up as it was such a good fit. I'm starting to wonder what Anthony Dyer is doing for his money? I guess these things take time.

Starting to get really interesting now for sure...

Left of field:-

Picked this company up from Twitter

I'm researching potential "partner" matches. My gut feeling is that its more likely a smaller lab/ business than a competing business in the LFT space. Also the RNS did not say "In partnership on a split revenue basis" or anything of that nature. We are still awaiting an acquisition. Feels more likely a partner they can bring in as part of the group?

Partner / possible acquisition target. Has supported AZN so will likely be known to Novacyt, this could be a fit?

https://aptamergroup.com/
Optimer™ reagents are next-generation aptamers that function as ideal affinity reagents for a range of diagnostic tests and assays, including ELISA, lateral flow devices, biosensors, and affinity chromatography.

@Dazzerman4
Totally agree that the USA market is the one to crack for sure.
Boots on the ground in New York and as you say appointment of Guillermo are big factors. Also they completed a number of key validation and documentation requirements in order to enable them to pitch for US Government contracts. Like you I am waiting for something significant to drop here for sure.

Outside of the USA, the situation in Canada also requires support. 38m population so again its a fairly decent size. Top market for viability is Japan if we could make inroads there.

Appreciate that India is a high volume country and in a real mess but unless they can do deals at the right price points they can supply the same kit to other countries at better prices. World wide demand remains incredibly high.

Good Luck

In the spirit of fun..

I think the Antigen partner more likely another specialist small Lab / business they have links with already and it wouldn't surprise me if it becomes a wholly owned subsidiary solely dedicated to LFT design and production. Probably why it wasn't disclosed at this point as a deal still being done hence, we can only speculate. They didn't say in conjuction with X company on a revenue share basis did they?

They did significant work with AZN regarding the saliva tests and now we find that was slipped into the update in the deal to support Airports. So you can never rule out AZN due to teh close working relationship but for this specific product i just think its a small lab - time will tell.

Yet another revenue field....

“I Know a few Investors”

Reminder that Novacyt only have 70m of Shares in Issue

That is a very small number compared to other companies on the stock market.

Circa 12% in II hands and balance close now to 50/50 U.K. / France

I now a few personal investors including myself that own chunks of stock and none of us are interested in anything under £25 either

It won’t take much buying pressure for this to rally going from no volume to possibly massive volume next week

Just Saying.....

We discussed Canada a number of times.
Another substantial market in need of support:-

https://www.ctvnews.ca/health/coronavirus/things-are-going-to-get-worse-canada-s-7-day-average-reaches-more-than-8-200-covid-19-cases-1.5396978
“Things are going to get worse in the next few weeks. ICU admissions are still coming in large numbers,” he said. “The system in Ontario is going to be stretched far beyond it’s ever been stretched before.”

Just truly shocking

With everything going on Friday and the vast amount of elements in that blockbuster RNS i genuinely lost sight of the title, you are absolutely right "UK Operational"

Are we shortly about to see a "USA Operational" Update??? OR some other Country regional update

It just gets better....

GLA

@Sharedealer2019
Brilliant spot - Thanks

Looks like the DHSC department now clearing out the historic issues. Absolutely Brilliant. So they should..

Now with Any luck, wouldn't it be something if it turned out the dispute was over Novacyt putting kit aside for the minimum contract value of £ 150m and then DHSC trying to wiggle out of paying for it!!!.

We know from the invoice count we are about £ 27m light - Just imagine if that was it and we could now invoice for the full contract value!! The markets have been speculating the worst here that this dispute will affect earnings negatively, when it could in fact turn out to be the exact opposite :)

Wishful thinking.....